Responder rates, a better way to express drug efficacy: data from darifenacin pooled phase III studies

Abrams P1, Foot J2, Lheritier K3, Steel M3 1. Bristol Urological Institute, Southmead Hospital, Bristol, UK, 2. Midtown Urology and Surgical Center, Atlanta, USA, 3. Novartis Pharma AG, Basel, Switzerland

Abstract Category

Detrusor Overactivity

Abstract 389
Read By Title:
Scientific Non Discussion Abstract Session 21